Health Topics — Metabolic & Cognitive
The Cortisol-Metabolism Connection
How the body's stress hormone disrupts metabolism when it stays elevated too long — the pathway from chronic stress to insulin resistance, and where the endocannabinoid system fits into that picture.
Cortisol is a survival hormone. Under acute stress it does exactly what it should. The problem arises when the stress that activates it doesn't stop — and what begins as an adaptive response becomes a sustained disruption to some of the body's most fundamental metabolic processes.
What Cortisol Is Actually For
Cortisol — the primary glucocorticoid hormone released by the adrenal glands in response to stress — has a specific evolutionary purpose: to make energy available fast. When the brain detects a threat, it activates the HPA axis — the hypothalamic-pituitary-adrenal pathway, the hormonal chain of command that coordinates the stress response — and cortisol floods the bloodstream within minutes. It raises blood glucose by triggering the liver to release stored sugar. It suppresses digestion, reproduction, and immune activity — processes that don't matter during an emergency. It sharpens attention and prepares muscles for action.
In the context of an acute physical threat that resolves in minutes, this cascade is elegantly designed. The threat passes, cortisol levels drop, the body returns to baseline. The problem the modern stress environment creates is a threat that doesn't resolve — psychological stress from work, finances, relationships, and chronic uncertainty that activates the same cascade repeatedly, day after day, without the physical resolution that dissipates it. The same hormone doing the same job, over and over, in a context where the job never gets finished.
The Metabolic Cascade: From Chronic Cortisol to Disrupted Glucose
The metabolic consequences of chronically elevated cortisol follow a fairly consistent biological sequence. Understanding the steps individually makes the overall picture — and where the ECS intersects it — easier to follow.
Sustained Glucose Release
Cortisol signals the liver to produce and release glucose — blood sugar — through a process called gluconeogenesis, meaning the liver manufactures new glucose from non-sugar sources like amino acids and fat. Under acute stress this is essential. Under chronic stress it means blood glucose is persistently elevated even without food intake.
Insulin Resistance Develops
Insulin — the hormone produced by the pancreas that tells cells to absorb glucose from the blood — faces sustained high glucose levels. Over time, cells in muscle, fat, and liver tissue become less responsive to insulin's signal, a condition called insulin resistance. The pancreas compensates by producing more insulin, but cells respond less effectively. Blood glucose remains elevated even as insulin levels rise.
Visceral Fat Accumulation
Cortisol specifically promotes fat storage in visceral adipose tissue — the deep abdominal fat that surrounds internal organs, as distinct from subcutaneous fat just under the skin. Visceral fat is metabolically active in ways that worsen the situation: it releases pro-inflammatory cytokines — signaling molecules that promote inflammation — and free fatty acids that further impair insulin signaling, creating a reinforcing cycle.
Appetite and Craving Dysregulation
Chronically elevated cortisol disrupts the hormones that regulate hunger — specifically ghrelin, which signals hunger, and leptin, which signals fullness. The net effect is increased appetite, particularly for calorie-dense, high-sugar, and high-fat foods. This is not a failure of willpower; it is a direct hormonal consequence of sustained stress exposure that makes metabolic recovery more difficult.
Systemic Inflammation
Acute cortisol is anti-inflammatory — one of its jobs is to suppress immune overactivation. But chronic cortisol exposure paradoxically produces the opposite effect over time: tissues develop glucocorticoid resistance, meaning they stop responding to cortisol's anti-inflammatory signal, while the pro-inflammatory cytokines released by visceral fat accumulate. The result is low-grade systemic inflammation that compounds metabolic disruption.
Where the Endocannabinoid System Intersects the Cascade
The endocannabinoid system — the body's network of cannabinoid receptors, the molecules that activate them, and the enzymes that regulate their levels — is not a bystander in this metabolic cascade. It is embedded in the pathway at several points, both as a contributor to the disruption under chronic stress and as a potential regulatory influence on it.
What CBG's Stress Research Suggests in This Context
The Cuttler et al. (2024) human trial — the only published randomized controlled trial of CBG in humans — examined stress, anxiety, and mood outcomes in healthy adults. It found significant reductions in perceived stress and anxiety in the CBG group relative to placebo. The trial did not measure metabolic outcomes. No cortisol levels were taken, no insulin sensitivity was assessed, no glucose measurements were made. These are important absences to state clearly.
What the trial's findings suggest in the context of this article is a potential upstream effect: if CBG reduces the subjective and physiological burden of the stress response, the downstream metabolic consequences of chronic cortisol elevation — the cascade described above — may be less likely to develop or sustain. This is a plausible biological hypothesis, not an established finding. The logic is sound because the biology connecting stress reduction to metabolic protection is well-documented in other contexts. The specific question of whether CBG's stress-modulating effects translate to measurable metabolic benefit has not been tested.
The Research Gap — Stated Directly
No human study has examined CBG's effects on cortisol levels, insulin sensitivity, blood glucose, or any other direct metabolic marker. The connection between CBG's documented stress effects and the metabolic pathway described in this article is a mechanistically grounded hypothesis supported by the biology. It is not established by evidence. Articles in the subsequent pillar address the preclinical research on cannabinoids and glucose regulation directly — including the PPAR-γ mechanism that links CBG's neuroinflammatory and metabolic profiles. That research exists at the preclinical level. Human metabolic trials of CBG have not been conducted.
Why This Pathway Matters Beyond Metabolic Disease
The cortisol-metabolism cascade is not only relevant for people concerned about metabolic conditions. The same pathway that drives insulin resistance and visceral fat accumulation also impairs cognitive function, disrupts sleep, amplifies anxiety, and accelerates biological aging through inflammatory mechanisms. These consequences compound each other — poor sleep elevates cortisol the following day, elevated cortisol further disrupts sleep, and both impair the metabolic regulation that depends on restorative rest.
This interconnection is why the Metabolic & Cognitive Health pillar exists as a combined category rather than two separate ones. The stress response, cognitive function, and metabolic health are not parallel systems that occasionally touch. They are a single integrated biological state whose components regulate each other continuously. Understanding the cortisol-metabolism pathway — and the endocannabinoid system's position within it — is foundational for understanding why stress management is not merely a psychological concern but a metabolic one as well.
References
- Björntorp, P., & Rosmond, R. (2000). Obesity and cortisol. Nutrition, 16(10), 924–936.
- Cuttler, C., Stuber, J., Cooper, Z.D., et al. (2024). The effects of cannabigerol on stress, anxiety, and mood: A randomized, double-blind, placebo-controlled trial. Scientific Reports, 14, 4306.
- Di Marzo, V., Côté, M., Matias, I., et al. (2009). Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: Associations with changes in metabolic risk factors. Diabetologia, 52(2), 213–217.
- Hill, M.N., McLaughlin, R.J., Bingham, B., et al. (2010). Endogenous cannabinoid signaling is essential for stress adaptation. Proceedings of the National Academy of Sciences, 107(20), 9406–9411.
- Kyrou, I., & Tsigos, C. (2009). Stress hormones: Physiological stress and regulation of metabolism. Current Opinion in Pharmacology, 9(6), 787–793.
- Pagotto, U., Marsicano, G., Cota, D., et al. (2006). The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine Reviews, 27(1), 73–100.
- Rosmond, R. (2005). Role of stress in the pathogenesis of the metabolic syndrome. Psychoneuroendocrinology, 30(1), 1–10.
These statements have not been evaluated by the Food and Drug Administration. J.P. Hemp Company products are not intended to diagnose, treat, cure, or prevent any disease.